Genzyme Belgium Genzyme Corporate Search Contact us
HealthcarePatients & FamiliesPractical Info
A disease with many faces
 
Healthcare Professionals
About Lysosomal Storage Disease
Gaucher
Fabry
MPS I
Disease Information
Management of MPS I Disease
Symptomatic or corrective management
Specific therapies
About AldurazymeŽ
AldurazymeŽ clinical trial summary
Reconstitution & Administration
Importance of Compliance
Summary of Product Characteristics
Medical Information Services
MPS I Registry
Practical Info
Request Materials
Pompe

 



  

MPS I Disease

Summary of Product Characteristics

MPS I – AldurazymeŽ

Click here for Dutch version (PDF)
Click here for French version (PDF)
 
Print

PRINT

 		Bookmark

BOOKMARK



01/01/2007: Low bone density in Gaucher disease improves with CerezymeŽ

01/05/2007: Treatment for Pompe disease now available for Belgian patients

01/03/2006: Early treatment with FabrazymeŽ significantly slows progression of Fabry

More >


Lysosomal Storage Disorders
General information
Gaucher Disease
Fabry Disease
MPS I Disease
Pompe Disease


 

Terms and Conditions of Use | Privacy Policy | © 2012 Genzyme Corporation, a Sanofi Company. All rights reserved.